Gabify has raised $175,000 in a pre-seed funding round led by Inflection Point Ventures. In addition, the startup has secured ₹25 lakh under the Nidhi Seed Support Scheme from the GH Raisoni Technology Business Incubator Foundation, further strengthening its early-stage funding base.
The newly raised capital will be used to advance clinical validation, enhance the platform’s technology capabilities, and expand its team. The company also plans to scale its reach through a mix of B2B, B2C, and CSR-driven models, with a long-term goal of impacting one million children by 2028.
Founded in 2023 by Sahil Chopra, Prachi Sood, and Vasyl Leshchuk, Gabify is developing an AI-powered platform focused on early screening and therapy management for neurodevelopmental conditions such as autism and ADHD.
The platform leverages a dual AI approach that combines voice and vision analysis to evaluate speech patterns, facial expressions, and behavioural signals. These insights are based on clinically validated parameters aligned with established diagnostic frameworks, while a human-in-the-loop system ensures that clinicians validate AI outputs for accuracy and reliability.
Designed as an end-to-end SaaS solution, the platform supports multilingual use, operates efficiently in low-bandwidth environments, and is built to be scalable, including deployment in underserved and rural settings.
Gabify has already tested its solution across more than 35 preschools and daycare centres, and is currently being used by schools, hospitals, clinics, NGOs, and independent practitioners.
The startup is also part of Inflection Point Ventures IdeaSchool and has been recognised among the top 10 startups under DreamDeal, an initiative led by Anupam Mittal. It has further gained visibility through participation in global platforms such as UNDP Youth Co:Lab.
As demand for accessible and technology-driven early intervention grows, Gabify aims to build a scalable ecosystem that improves early diagnosis and therapy outcomes, particularly in regions where access to specialised care remains limited.
